This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $500 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
December 4 - 8, 2022
Marriott Marquis San DiegoDelivered as a Hybrid Event

Rob Roovers
Senior Director, Preclinical Development at LAVA Therapeutics


A (bio-)chemist by training, I did a PhD in antibody phage display, antibody engineering and the development of human(ized) antibodies for therapeutic and diagnostic oncology applications. After a post-doc in academia, I started collaborating (from within the university) with Biotech companies for the development of therapeutic antibodies in oncology. After a couple of years, I joined the early ranks of Merus and co-developed several bispecifics that are now being tested in phase 1 and 2 trials, before I entered LAVA Therapeutics as one of the first employees. My current responsibility as head of preclinical development encompasses the development of the pipeline of LAVA, from panel generation to the writing of the IB to support CTA/IND.

Agenda Sessions

  • Workshop Co-Moderator’s Remarks

  • Functional Screening, Characterization and Optimization of Antibody Leads